Industry Overview
In 2007, the size of the global pharmaceutical market was US$ 959 bn. The market has since grown at a CAGR of nearly 30% from 2007-to 2012. Oncologic and Analgesics were the top-selling therapeutic classes in 2012. During 2007–12 Asia remained the fastest-growing Pharmaceuticals market, followed By Latin American and North America.
The Indian market is among the top emerging pharmaceutical markets and is expected to grow over 15 percent per annum between 2015 and 2020. Many companies are coming up with new products as the old, and patented products are going out of product. Most Indian companies manufacture API, Formulations and export them to the US and Europe. Demand for Indian Pharmaceuticals products is increasing all over the world as the cost of healthcare is growing all over the world. As per one estimate, the export value of Indian Pharma products will be US$ 25 compared to a market size of 36 Billion. Future growth for Indian companies will come from France, Spain, and Italy.
In India, Anti infectivity, gastrointestinal, and cardiovascular hold the Highest market Share total of 39%
Company overview: Lupin limited Mumbai Based company, the Second largest Pharma company in India, the 14th largest producer of generic drugs worldwide, and the 5th largest generic drug producer worldwide. The company operates in Developing generic drugs and research also. Dr. Desh Bandhu Gupta, Promoter of the company, was a former professor of BITS Pilani. The company manufactures major medications for common illnesses: Asthma, TB, Diabetes, Cardiovascular problems, and NSAIDs. The company is widely spread all over WORLD, South Africa, the USA, Japan, Australia, the Philippines, and Europe. As it was the Anti-TB Drug that made Them well known worldwide, Lupin partnered with the government for the revised national TB program to help with its fight against TB in the country.
R&D activity is essential in the pharmaceutical industry, and LUPIN knows it. Unfortunately, many companies forget it all over the industry and only concentrate on API and Formulation. But Lupin knows the importance of R&D.
Lupin set up large headquarters for R&D and is located in Pune, where nearly 1200 scientists work on developing new drugs. They also have a lot of research on the latest drug delivery systems like the ADDS (advanced drug delivery systems) and the NDDS (Novel drug delivery systems) that could change the world shortly.
SHAREHOLDING BSE Data
Financials and Ratios : [table id=21 /]
Future Prospects: Pharma company is operating in a significant segment with good growth.
Recently there have been some issues with the Goa plant, but that is now close. However, the company received permission for the new plants and new API, and as research is needed, it is an essential company.
